

1103326-0072

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Lindberg et al.
 Serial No. : 09/690,044
 Filed : October 16, 2000
 For : NEW COMPOUNDS
 Examiner : J. Fan
 Group Art Unit : 1625

OK
 83
 10/2/03

#10

CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. §1.8	
I hereby certify that this paper is being facsimile transmitted to the United States Patent and Trademark Office on January 30, 2003 at the facsimile number <u>703-308-4734</u> .	
John M. Genova Agent Name	32,224 PTO Reg. No.
<i>John M. Genova</i> Signature	30 January 2003 Date of Signature

Assistant Commissioner for Patents
 Washington, D.C. 20231

02/13/2003 HPF0015 00000006 231
 01 FC:1814
 Attention: Examiner Jane Fan
 Facsimile No.: 703-308-4734
 Date: January 30, 2003
 Pages: 3

TERMINAL DISCLAIMER

Sir:

AstraZeneca, a corporation created and existing under the laws of Sweden, and having a business address at S-151 85 Södertälje, Sweden, hereby through its undersigned agent, who is empowered to act on behalf of AstraZeneca, represents that AstraZeneca is the owner of the entire right, title and interest of the above-identified patent application Serial No. 09/690,044

BEST AVAILABLE COPY

and US 5,714,504 by Assignment recorded on January 23, 1995 at Reel 7438, Frame 0120, and of US 5,877,192 by Assignment recorded on November 14, 1997 at Reel 8814, Frame 0101.

The originally recorded assignments are in the name of Astra Aktiebolag. A change of corporate name from Astra Aktiebolag to AstraZeneca was recorded on September 25, 2000 at Reel 011219, Frame 0749.

AstraZeneca, by its undersigned agent, states that all evidentiary documents have been reviewed and certifies that, to the best of its knowledge and belief, title to Application Serial No. 09/690,044, US 5,714,504 and US 5,877,192 is in AstraZeneca. The inventions claimed in Application Serial No. 09/690,044, US 5,714,504 and US 5,877,192 were commonly owned by Astra Aktiebolag, now AstraZeneca at the time the later invention was made.

AstraZeneca hereby disclaims, except as provided below, the terminal portion of the statutory term of any patent granted on the above-identified application which would extend beyond the expiration date of the full statutory term as defined in 35 U.S.C. §§154 to 156 and 173 of either of prior US 5,714,504 and US 5,877,192. AstraZeneca hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period it and US 5,714,504 and US 5,877,192 are commonly owned. This agreement runs with any patent granted on the above-identified application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, petitioner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§154 to 156 and 173 of either of US 5,714,504 and US 5,877,192, in the event that either prior patent: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321, has all claims canceled by

a reexamination certificate, is reissued or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Authorization is hereby given to charge Deposit Account No. 23-1703 in the amount of One Hundred and Ten Dollars (\$110.00) to cover the fee as required by 37 C.F.R. §1.20(d) and for any other fee that may be required in connection with this communication.

Dated: January 30, 2003

Respectfully submitted,



John M. Genova
Reg. No. 32,224
Attorney for Applicants

Client No. 007470
Attorney Direct Dial (212) 819-8832

BEST AVAILABLE COPY